Latest news with #Post-TraumaticStressDisorder
Time of India
15 hours ago
- Entertainment
- Time of India
Anshula Kapoor says she was diagnosed with PTSD after elimination from 'The Traitors', calls the show extremely difficult
Anshula Kapoor was recently seen in the OTT reality series 'The Traitors', hosted by Karan Johar . Adapted from the international format of the same name, the show brings together 20 celebrity contestants, who are placed under high-pressure conditions in pursuit of a grand prize. The gameplay revolves around secrecy and psychological tactics. Anshula Kapoor reveals the hardships she faced in The Traitors After being eliminated from the show, Anshula opened up about the emotional toll it had taken on her. Speaking to The Quint, she revealed that her mental health had suffered significantly during the filming. 'Living without communication with the outside world for the entire duration of the show was extremely difficult,' she shared. Anshula described the situation as 'stressful' and 'traumatising.' She explained that she had agreed to participate under the impression that the Indian adaptation would closely follow the original international format. While she did not struggle with the long filming hours, it was the atmosphere that felt suffocating. 'There were no intercoms in our room. They had blacked out our room numbers, so we didn't know our own or anyone else's room number. They had placed wind chimes outside our room doors, and if you opened the door when you weren't supposed to, someone would come and tell you not to leave your room,' she recalled. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Costco Shoppers Say This Wrinkle Cream Is "Actually Worth It" The Skincare Magazine Undo Uorfi Javed vs Apoorva Mukhija: 'The Traitors' Reality Show Fight Gets UGLY Anushula Kapoor about the traumatic atmosphere The lack of communication and the constant surveillance took a toll on her mental well-being. 'I had to go back into intensive therapy after the show, and I was diagnosed with Post-Traumatic Stress Disorder,' Anshula disclosed. She also clarified that she had no prior PTSD diagnosis before entering the show. Anshula reacted to whether the show is scripted or not Earlier, Anshula had shared an Instagram story highlighting the secrecy surrounding the show. 'There was so much secrecy. We weren't told who our fellow participants would be. When we were flying from Bombay to shoot for this, I think Elnaz, Ashish ji, Sufi, and Jannat were on my flight. To keep it as secret as possible, even during the check-in process at the airport, we were given different slots. We were each assigned a 'shadow'—our own personal valet,' she wrote. About The Traitors The Traitors premiered on one of the leading OTT platforms on June 12. New episodes are released weekly every Thursday at 8 PM, leading up to the grand finale scheduled for July 3.
Associated Press
5 days ago
- Business
- Associated Press
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a prominent government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments. As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S.. The company's partnered with the esteemed firm to support the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks. 'We are pleased to collaborate with a team of seasoned government affairs experts to help shape the future of psychedelic medicine,' said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. 'Psychedelics hold immense promise for transforming mental health treatment, but their novelty requires proactive engagement with regulators and policymakers to ensure safe and equitable access. This partnership underscores our commitment to driving progress in this rapidly evolving field.' The consulting firm, known for its expertise in navigating federal and state regulatory environments, will work closely with Clearmind to educate policymakers on the therapeutic potential of psychedelics, support the development of balanced regulations, and foster strategic alliances to advance the company's innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for AUD at prestigious institutions like Yale School of Medicine and Johns Hopkins University. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations [email protected] Telephone: (604) 260-1566 US: [email protected] General Inquiries [email protected] Forward-Looking Statements:
Yahoo
5 days ago
- Business
- Yahoo
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a prominent government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments. As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S.. The company's partnered with the esteemed firm to support the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks. 'We are pleased to collaborate with a team of seasoned government affairs experts to help shape the future of psychedelic medicine,' said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. 'Psychedelics hold immense promise for transforming mental health treatment, but their novelty requires proactive engagement with regulators and policymakers to ensure safe and equitable access. This partnership underscores our commitment to driving progress in this rapidly evolving field.' The consulting firm, known for its expertise in navigating federal and state regulatory environments, will work closely with Clearmind to educate policymakers on the therapeutic potential of psychedelics, support the development of balanced regulations, and foster strategic alliances to advance the company's innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for AUD at prestigious institutions like Yale School of Medicine and Johns Hopkins University. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relationsinvest@ Telephone: (604) 260-1566US: CMND@ General InquiriesInfo@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
Daily Record
18-06-2025
- Entertainment
- Daily Record
Veterans' charity to host Lanarkshire's first Armed Forces Family Fun Day
Who Dares Cares is a dedicated United Kingdom Armed Forces and blue light services charity Lanarkshire locals are being encouraged to support our veterans at the inaugural Armed Forces Family Fun Day. Organised by Who Dares Cares charity, the event at Calderglen Country Park in East Kilbride on Sunday, June 29, will support veterans and blue light services. Attractions on the day include military vehicles, pipe bands, an inflatable assault course, face painting, stalls, a DJ and music, military memorabilia and Police Scotland and Mountain Rescue will also be on hand to chat to visitors. Download the Lanarkshire Live app today The Lanarkshire Live app is available to download now. Get all the news from your area – as well as features, entertainment, sport and the latest on Lanarkshire's recovery from the coronavirus pandemic – straight to your fingertips, 24/7. The free download features the latest breaking news and exclusive stories, and allows you to customise your page to the sections that matter most to you. Head to the App Store and never miss a beat in Lanarkshire - iOS - Android Event organiser and army veteran Calum McLeod, who co-founded Who Dares Cares charity, said: "It's going to be a great day with the military vehicles, including original SAS vehicles from the Second World War, being the main attraction. The only thing we need now is the weather to be on our side! "Who Dares Cares is a veterans' charity. We are in East Kilbride quite a bit - a lot of the veterans come from East Kilbride so Calderglen was a good choice for this event. "It will be a family day for all, open to the public, and this will be the first event of its kind here in Lanarkshire. "There was nothing like the big Armed Forces Day parades you get in Glasgow here in Lanarkshire so this is how the idea came about." Who Dares Cares is a dedicated United Kingdom Armed Forces and blue light services charity based in Hamilton. Formed through Alba Military Fitness, the charity was founded by two former soldiers Colin MacLachlan, The Royal Scots & 22 SAS and Calum MacLeod, the King's Own Scottish Borderers. Both servicemen left the army, but for them the wars were not over. They decided to support other veterans too. Their mission is to support Armed Forces and blue light services personnel, including their families, who are suffering from Post-Traumatic Stress Disorder (PTSD). Calum added: "In Lanarkshire alone there are 20,000 veterans. So the idea was to put on a family fun day to bring everyone together. "The charity started with four people and is now UK-wide and is heavily involved in various events throughout the year. We're just back from the West Highland Way with a group of veterans and we run a Walk - Talk - Brew mental health group every fortnight in Calderglen Country Park and at Strathclyde Country Park. "We're all volunteers who still have day jobs but the charity has just grown arms and legs. We were the first to do a walk and talk event for mental health and now it's evolved into something so much more." Armed Forces Family Fun Day runs from 12-4.30pm and entry and parking is free. *Don't miss the latest headlines from around Lanarkshire. Sign up to our newsletters here.
Time Business News
16-06-2025
- Health
- Time Business News
Understanding Dual Diagnosis: When Addiction and Mental Health Collide
When addiction and mental illness occur simultaneously, the result is a condition known as dual diagnosis. This complex and often misunderstood intersection presents significant challenges in treatment and recovery. Individuals with dual diagnosis face an uphill battle, as two intricately woven conditions fuel and exacerbate each other. Understanding this phenomenon is not only crucial for treatment providers but also for the broader public, who must recognize the layered struggles these individuals endure. When a person takes a prescription medication like Suboxone, it's essential to understand how long its effects can linger in the system. This knowledge helps in managing treatment, avoiding interactions, and preparing for medical tests. How Long does suboxone stay in your system depends on several factors, including dosage, metabolism, liver function, and duration of use. Generally, Suboxone can be detected in urine for up to 7–10 days, in blood for up to 4 days, and in saliva for several days after the last dose. Always consult a healthcare professional for guidance specific to your health condition. Dual diagnosis refers to the co-occurrence of a substance use disorder and a mental health disorder within the same individual. This isn't merely a coincidental overlap—it's a multifaceted clinical condition requiring nuanced care. Many individuals oscillate between psychiatric treatment and addiction recovery, often falling through the cracks of siloed health systems. Misdiagnosis is common, as substance use can mimic or obscure psychiatric symptoms, leading to fragmented care that addresses only one aspect of the individual's reality. Depression frequently coexists with substance abuse. Individuals grappling with persistent sadness, fatigue, and hopelessness may turn to alcohol or drugs for temporary reprieve. However, the numbing effect of substances often deepens depressive symptoms, creating a perilous feedback loop that intensifies both conditions. Anxiety disorders, including generalized anxiety and panic disorder, are among the most frequently associated with addiction. Many individuals attempt to quell their restlessness, fear, or social anxiety with sedatives or stimulants, inadvertently fostering dependency while their anxiety disorder festers unresolved. Bipolar disorder introduces unique complexities, as individuals may use substances during both manic highs and depressive lows. The manic phase may drive impulsivity and risky behaviors, while the depressive phase may push toward sedation. This erratic pendulum fuels an unpredictable addiction pattern that complicates diagnosis and treatment. Post-Traumatic Stress Disorder is another frequent companion to addiction. Traumatic memories and hypervigilance lead many individuals to seek solace in drugs or alcohol. Unfortunately, substances impair the brain's natural healing process and can exacerbate dissociative symptoms, making PTSD more severe and chronic. The relationship between addiction and mental illness is deeply symbiotic. Mental health disorders can precipitate substance abuse, while addiction can unearth or intensify latent psychiatric symptoms. Brain chemistry plays a pivotal role—substance use alters dopamine, serotonin, and other neurotransmitters that also regulate mood and cognition. Over time, neuroplastic changes embed maladaptive behaviors, making recovery more arduous. Additionally, shared environmental triggers, such as trauma, poverty, and familial dysfunction, compound the risk of both conditions emerging in tandem. Diagnosing dual diagnosis is akin to navigating a hall of mirrors—each symptom reflecting and distorting the other. Clinicians often struggle to determine whether the psychiatric symptoms stem from addiction, vice versa, or both. This diagnostic ambiguity is further complicated by stigma, which deters individuals from seeking help or disclosing full details. Clinical biases may result in professionals prioritizing one disorder over the other, leading to incomplete care. Furthermore, a lack of standardized, integrated screening protocols means many dual diagnosis cases remain undetected until crises emerge. Treating dual diagnosis demands a synchronized approach. Traditional models that treat addiction and mental health separately are insufficient. Instead, integrated treatment—where both disorders are addressed concurrently within the same therapeutic framework—proves more effective. Evidence-based practices like Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Trauma-Informed Care are essential. Medication-assisted treatment (MAT), when combined with psychiatric support, helps stabilize chemical imbalances and mitigate cravings. Successful programs prioritize personalized care plans that evolve with the individual's progress and setbacks. Recovery from dual diagnosis doesn't end with clinical treatment—it extends into the fabric of everyday life. A strong support network, including family, peers, and community resources, is indispensable. Support groups tailored for dual diagnosis individuals provide safe spaces for shared experiences and encouragement. Aftercare planning, including sober living environments, outpatient therapy, and relapse prevention strategies, lays the groundwork for sustainable recovery. Empowering individuals to pursue purpose-driven goals—whether through employment, education, or creative expression—fosters resilience and reduces relapse risk. Dual diagnosis is a formidable challenge that requires compassion, comprehension, and collaboration. By acknowledging the interconnected nature of addiction and mental illness, and by adopting integrated, stigma-free approaches, society can offer real hope to those caught in this complex web. Understanding dual diagnosis is not merely a clinical concern—it's a moral imperative that calls for collective responsibility and innovative care. TIME BUSINESS NEWS
